{"id":"interferon-alpha","safety":{"commonSideEffects":[{"rate":"80-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"50-70","effect":"Headache"},{"rate":"40-60","effect":"Myalgia"},{"rate":"30-50","effect":"Anorexia"},{"rate":"20-40","effect":"Nausea"},{"rate":"20-30","effect":"Leukopenia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"10-30","effect":"Depression/mood changes"},{"rate":"5-15","effect":"Thyroid dysfunction"}]},"_chembl":{"chemblId":"CHEMBL2108506","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon-Alpha is a cytokine that binds to type I interferon receptors (IFNAR) on the surface of immune cells and other tissues. This binding triggers intracellular signaling cascades that upregulate antiviral proteins, enhance natural killer cell and macrophage activity, and promote apoptosis in malignant cells. It also has direct antiproliferative effects on tumor cells and can enhance MHC expression to improve immune recognition.","oneSentence":"Interferon-Alpha activates the innate immune system by binding to interferon-alpha receptors on immune cells, enhancing their antiviral and anti-tumor activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:19.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML)"},{"name":"Melanoma"},{"name":"Renal cell carcinoma"},{"name":"Hepatitis B"},{"name":"Hepatitis C"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT02506153","phase":"PHASE3","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-10","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma","enrollment":1301},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":"Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm","enrollment":427},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT04380545","phase":"PHASE1, PHASE2","title":"Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-13","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8","enrollment":15},{"nctId":"NCT01125228","phase":"","title":"Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1988-10-19","conditions":"HIV","enrollment":180},{"nctId":"NCT00003641","phase":"PHASE3","title":"High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1999-03-25","conditions":"Melanoma (Skin)","enrollment":1150},{"nctId":"NCT04093323","phase":"PHASE2","title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-13","conditions":"HLA-A2 Positive Cells Present, Refractory Melanoma","enrollment":1},{"nctId":"NCT01274338","phase":"PHASE3","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-25","conditions":"Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7","enrollment":1673},{"nctId":"NCT06716853","phase":"PHASE1, PHASE2","title":"A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Genenta Science","startDate":"2024-10-22","conditions":"Clear Cell RCC","enrollment":10},{"nctId":"NCT03866109","phase":"PHASE1, PHASE2","title":"A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genenta Science","startDate":"2019-03-05","conditions":"Glioblastoma Multiforme","enrollment":27},{"nctId":"NCT07135349","phase":"PHASE2","title":"A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Argo Biopharmaceutical Co., Ltd.","startDate":"2025-09-02","conditions":"Chronic Hepatitis B","enrollment":209},{"nctId":"NCT04379518","phase":"PHASE1, PHASE2","title":"Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2020-11-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed","enrollment":4},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT01708941","phase":"PHASE2","title":"Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-01-18","conditions":"Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7","enrollment":88},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":"Chronic Hepatitis b","enrollment":43},{"nctId":"NCT02201459","phase":"PHASE3","title":"Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-08","conditions":"Chronic Myeloid Leukemia","enrollment":200},{"nctId":"NCT05970289","phase":"PHASE2","title":"Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2023-08-22","conditions":"Chronic Hepatitis B Virus Infection","enrollment":86},{"nctId":"NCT06545812","phase":"NA","title":"Immune Response During the Conservative and Minimal Invasive Treatment of Pain Caused by Lumbar Disc Herniation","status":"RECRUITING","sponsor":"Josip Juraj Strossmayer University of Osijek","startDate":"2024-09-02","conditions":"Intervertebral Disc Herniation, Back Pain, Analgesic Nephropathy","enrollment":128},{"nctId":"NCT03899987","phase":"PHASE2","title":"Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2019-11-29","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8","enrollment":12},{"nctId":"NCT00015847","phase":"PHASE2","title":"Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2001-04","conditions":"Leukemia","enrollment":25},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT02533258","phase":"","title":"Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-12-02","conditions":"Renal Cell Carcinoma","enrollment":13},{"nctId":"NCT02992704","phase":"PHASE2, PHASE3","title":"Peg-interferon for Inactive Chronic Hepatitis B Carriers","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2016-08","conditions":"Chronic Hepatitis, B Virus, Carrier of Viral Hepatitis Type B","enrollment":90},{"nctId":"NCT06047132","phase":"","title":"PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED SUBJECTS","status":"COMPLETED","sponsor":"Universidad Complutense de Madrid","startDate":"2023-10-23","conditions":"Periodontitis, Saliva, Biomarkers","enrollment":100},{"nctId":"NCT05756166","phase":"PHASE1, PHASE2","title":"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-02-16","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma","enrollment":5},{"nctId":"NCT06125535","phase":"","title":"Biomolecular Phenotyping of Lung Transplant Recipients","status":"COMPLETED","sponsor":"Policlinico Hospital","startDate":"2022-02-01","conditions":"Lung Transplant Failure","enrollment":80},{"nctId":"NCT06650852","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)","status":"RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-10-31","conditions":"Chronic Hepatitis B Virus (HBV) Infection","enrollment":250},{"nctId":"NCT02380443","phase":"PHASE2","title":"AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mirror Biologics, Inc.","startDate":"2016-09","conditions":"Colorectal Cancer Metastatic","enrollment":13},{"nctId":"NCT04418219","phase":"PHASE1, PHASE2","title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2020-12-21","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":""},{"nctId":"NCT06926647","phase":"","title":"A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-05-01","conditions":"HBV, Chronic Hepatitis b","enrollment":2000},{"nctId":"NCT00442572","phase":"PHASE2","title":"SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07-03","conditions":"Hepatitis B, Chronic","enrollment":21},{"nctId":"NCT01194037","phase":"PHASE1, PHASE2","title":"A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2011-06-23","conditions":"Chronic Hepatitis C Infection, Genotype 1","enrollment":30},{"nctId":"NCT04035837","phase":"PHASE4","title":"The Clinical Cure Project of Chronic Hepatitis B in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-05-16","conditions":"Hepatitis B, Chronic","enrollment":30000},{"nctId":"NCT06923280","phase":"NA","title":"Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-05-01","conditions":"Hepatitis B, Chronic","enrollment":30},{"nctId":"NCT06137950","phase":"PHASE1","title":"Interferon Alpha Therapy for Cervical CINI and HPV Infection","status":"COMPLETED","sponsor":"Mongolian National University of Medical Sciences","startDate":"2023-11-07","conditions":"Cervical Dysplasia, HPV Infection","enrollment":60},{"nctId":"NCT06827249","phase":"NA","title":"Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2025-03","conditions":"Bronchiolitis","enrollment":90},{"nctId":"NCT01986712","phase":"","title":"A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma","status":"COMPLETED","sponsor":"St. Luke's Hospital and Health Network, Pennsylvania","startDate":"2013-12","conditions":"Melanoma","enrollment":50},{"nctId":"NCT05850273","phase":"","title":"Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2023-03-16","conditions":"Myeloproliferative Neoplasm","enrollment":80},{"nctId":"NCT06802718","phase":"PHASE3","title":"Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-01-01","conditions":"Acute Myeloid Leukemia","enrollment":96},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT06491563","phase":"PHASE2","title":"Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-08-06","conditions":"For Treatment of Chronic Hepatitis B Virus Infection","enrollment":150},{"nctId":"NCT06734637","phase":"NA","title":"Efficacy and Safety of Peginterferon in ET and PV.","status":"RECRUITING","sponsor":"Zhenya Hong","startDate":"2024-11-20","conditions":"Essential Thrombocythemia, Polycythemia Vera","enrollment":40},{"nctId":"NCT00452023","phase":"PHASE2","title":"Pegasys® in Patients With Myeloproliferative Diseases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-04-07","conditions":"Myeloproliferative Disorders","enrollment":83},{"nctId":"NCT06091735","phase":"NA","title":"Clinical Study of Bowel Preparation Before Colonoscopy","status":"COMPLETED","sponsor":"Jinling Hospital, China","startDate":"2023-08-01","conditions":"Bowel Preparation","enrollment":444},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":"Polycythemia Vera","enrollment":586},{"nctId":"NCT04412863","phase":"PHASE2","title":"Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2020-07-03","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT06582017","phase":"PHASE1","title":"Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma","status":"RECRUITING","sponsor":"Nammi Therapeutics Inc","startDate":"2024-08-28","conditions":"Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma","enrollment":100},{"nctId":"NCT06535048","phase":"","title":"Impact of Fatty Liver on Hepatitis B Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Second People's Hospital","startDate":"2015-01-01","conditions":"Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment","enrollment":500},{"nctId":"NCT05781841","phase":"","title":"Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-04-15","conditions":"Warts","enrollment":100},{"nctId":"NCT06507891","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-07-06","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05244057","phase":"PHASE2","title":"A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2022-08-23","conditions":"Chronic Hepatitis B","enrollment":8},{"nctId":"NCT04226950","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-01-10","conditions":"Essential Thrombocytopenia","enrollment":40},{"nctId":"NCT05395507","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-01","conditions":"Essential Thrombocytopenia","enrollment":194},{"nctId":"NCT06222801","phase":"","title":"The 1st Tumor CytokinoTherapy Database (TCTD-1)","status":"RECRUITING","sponsor":"OncoCareClinic 308 Ltd","startDate":"2022-09-19","conditions":"Oncology","enrollment":5000},{"nctId":"NCT04676724","phase":"PHASE2","title":"Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-28","conditions":"Hepatitis B","enrollment":108},{"nctId":"NCT06277167","phase":"PHASE1","title":"A Phase I Study in Healthy Participants","status":"COMPLETED","sponsor":"Kexing Biopharm Co., Ltd.","startDate":"2023-01-07","conditions":"Healthy Participants","enrollment":35},{"nctId":"NCT06371235","phase":"NA","title":"Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier","status":"NOT_YET_RECRUITING","sponsor":"CerbaXpert","startDate":"2024-09","conditions":"Woman Suffering From a Pathology Frequently Associated With the Presence of These Anti-autoantibodies Type-I Interferons","enrollment":250},{"nctId":"NCT06356740","phase":"PHASE2","title":"Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-01","conditions":"Systemic Lupus Erythematosus","enrollment":70},{"nctId":"NCT04846491","phase":"PHASE3","title":"A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2019-12-04","conditions":"Chronic Hepatitis B","enrollment":475},{"nctId":"NCT00695019","phase":"PHASE2","title":"Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C","status":"COMPLETED","sponsor":"Ainos, Inc. (f/k/a Amarillo Biosciences Inc.","startDate":"2009-06","conditions":"Hepatitis C, Chronic","enrollment":169},{"nctId":"NCT04640129","phase":"PHASE4","title":"HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-01-01","conditions":"Liver Fibrosis","enrollment":336},{"nctId":"NCT05065905","phase":"PHASE1, PHASE2","title":"Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2006-01-19","conditions":"HIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary","enrollment":78},{"nctId":"NCT00002965","phase":"PHASE2","title":"Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1997-01","conditions":"Brain and Central Nervous System Tumors","enrollment":16},{"nctId":"NCT03638375","phase":"PHASE1, PHASE2","title":"TIL and Anti-PD1 in Metastatic Melanoma","status":"UNKNOWN","sponsor":"Leiden University","startDate":"2018-07-31","conditions":"Toxicity, Drug, Adverse Drug Event, Effects of Immunotherapy","enrollment":34},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT01545141","phase":"PHASE1, PHASE2","title":"Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2012-10","conditions":"Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors","enrollment":15},{"nctId":"NCT04781647","phase":"PHASE2","title":"A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2021-02-18","conditions":"Chronic Hepatitis B","enrollment":54},{"nctId":"NCT04664010","phase":"NA","title":"Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19)","status":"COMPLETED","sponsor":"Xi'an International Medical Center Hospital","startDate":"2020-02-06","conditions":"COVID-19","enrollment":30},{"nctId":"NCT00574730","phase":"NA","title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-05-23","conditions":"Non-Hodgkins Lymphoma","enrollment":27},{"nctId":"NCT04081389","phase":"PHASE1","title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-06","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8","enrollment":9},{"nctId":"NCT04534725","phase":"PHASE3","title":"COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2020-12-17","conditions":"Cancer, Covid19, Respiratory Viral Infection","enrollment":441},{"nctId":"NCT05729139","phase":"PHASE1","title":"Cemiplimab/Peg-Interferon-α in Advanced CSCC","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2023-07","conditions":"Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03599453","phase":"EARLY_PHASE1","title":"Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-01-09","conditions":"Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative","enrollment":8},{"nctId":"NCT02340962","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2015-05","conditions":"Hepatitis C, Chronic","enrollment":25},{"nctId":"NCT05941845","phase":"PHASE2","title":"Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-07-24","conditions":"Membranous Nephropathy","enrollment":5},{"nctId":"NCT00062010","phase":"PHASE2","title":"Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-05-26","conditions":"Lung Cancer","enrollment":37},{"nctId":"NCT01935089","phase":"PHASE2","title":"Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2013-08-07","conditions":"HIV-1 Infection","enrollment":20},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT00003027","phase":"PHASE3","title":"Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-11-13","conditions":"Melanoma (Skin)","enrollment":482},{"nctId":"NCT00002868","phase":"PHASE3","title":"Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-11-20","conditions":"Leukemia","enrollment":744},{"nctId":"NCT00005847","phase":"PHASE2","title":"Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2001-04-05","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00003444","phase":"PHASE3","title":"Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-03-29","conditions":"Melanoma (Skin)","enrollment":167},{"nctId":"NCT00003266","phase":"PHASE3","title":"Methylphenidate in Treating Patients With Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-10-12","conditions":"Fatigue, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":200},{"nctId":"NCT00054561","phase":"PHASE3","title":"Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2003-11-26","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT00134030","phase":"PHASE3","title":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-11-14","conditions":"Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1334},{"nctId":"NCT02063464","phase":"","title":"Blood Collection From People With Ovarian Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-10","conditions":"Ovarian Cancer, Cancer of the Ovary, Ovarian Neoplasms","enrollment":85},{"nctId":"NCT05863975","phase":"PHASE4","title":"Treatment of HPV Infection in Perimenopausal and Postmenopausal Women","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-07-01","conditions":"HPV Infection","enrollment":150},{"nctId":"NCT01657604","phase":"PHASE3","title":"TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study","status":"COMPLETED","sponsor":"University of Jena","startDate":"2012-08-24","conditions":"Chronic Myeloid Leukemia","enrollment":717},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT01359956","phase":"PHASE3","title":"Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2002-04","conditions":"Malignant Melanoma, Recurrent Melanoma","enrollment":269},{"nctId":"NCT03117816","phase":"PHASE3","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2017-05-04","conditions":"Chronic Myeloid Leukemia in Remission","enrollment":214},{"nctId":"NCT05792878","phase":"","title":"Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2022-09-01","conditions":"Chronic Hepatitis B, COVID-19 Infection","enrollment":600},{"nctId":"NCT04726553","phase":"EARLY_PHASE1","title":"Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE","status":"UNKNOWN","sponsor":"Oklahoma Medical Research Foundation","startDate":"2021-01-20","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":20},{"nctId":"NCT02776644","phase":"","title":"Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-15","conditions":"Renal Cell Carcinoma","enrollment":1349},{"nctId":"NCT04501783","phase":"PHASE3","title":"Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-05-20","conditions":"COVID-19","enrollment":168},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT02430181","phase":"PHASE2","title":"Lonafarnib With and Without Ritonavir in HDV (LOWR-1)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-11","conditions":"Chronic Hepatitis D Infection","enrollment":21}],"_emaApprovals":[],"_faersSignals":[{"count":184,"reaction":"HEPATIC FAILURE"},{"count":94,"reaction":"DRUG INEFFECTIVE"},{"count":76,"reaction":"ANAEMIA"},{"count":60,"reaction":"RASH"},{"count":59,"reaction":"HEPATITIS C"},{"count":54,"reaction":"FATIGUE"},{"count":50,"reaction":"NAUSEA"},{"count":43,"reaction":"THROMBOCYTOPENIA"},{"count":39,"reaction":"ASTHENIA"},{"count":36,"reaction":"PYREXIA"}],"_approvalHistory":[],"publicationCount":21843,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Interferon, alpha interferon, Intron® A, Roferon® A","Veldona","IFN-alpha lozenge","low dose IFN lozenge","Pegintron®, Schering Plough"],"phase":"marketed","status":"active","brandName":"Interferon-Alpha","genericName":"Interferon-Alpha","companyName":"University of Birmingham","companyId":"university-of-birmingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon-Alpha activates the innate immune system by binding to interferon-alpha receptors on immune cells, enhancing their antiviral and anti-tumor activity. Used for Chronic myeloid leukemia (CML), Melanoma, Renal cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}